肌缩性侧面硬化症的诊断标准
Hannah C Timmins1, Alexandra E Thompson1,2, Matthew C Kiernan1,3,4
1Neuroscience Research Australia.
Current opinion in neurology
|July 22, 2024
概括
新的黄金海岸共识标准 (GCC) 简化了肌缩性侧面硬化症 (ALS) 诊断,提高了早期检测的敏感性和更广泛的临床试验招生. 未来的生物标志物可能会进一步提高诊断效用.
科学领域:
- 神经学 神经学
- 临床诊断 临床诊断 临床诊断
背景情况:
- 肌缩侧面硬化症 (ALS) 的诊断依赖于特定的临床标准.
- 现有的标准,如修订的埃尔埃斯科里亚尔 (rEEC) 和阿瓦吉标准 (AC),具有局限性,特别是在非典型的呈现方面.
- 需要提高诊断灵敏度和更广泛的患者符合临床试验的资格.
研究的目的:
- 审查对肌缩侧面硬化症 (ALS) 的诊断标准的演变.
- 讨论黄金海岸共识标准 (GCC) 的发展和实用性.
- 考虑生物标志物在未来的ALS诊断中的作用.
主要方法:
- 对现有文献的审查和对诊断标准的共识发展.
- 黄金海岸共识标准 (GCC) 与之前的标准 (rEEC,AC) 的敏感性和实用性的比较.
- 评估GCC对临床试验招生的潜在影响.
主要成果:
- 黄金海岸共识标准 (GCC) 与rEEC和AC相比显示出类似或更大的敏感性,特别是在非典型的ALS表型方面.
- 在不同的疾病持续时间,严重程度和发病地点,GCC保持诊断灵敏度.
- 实施GCC可以将ALS患者在临床试验中的入学人数增加高达50%.
结论:
- 海湾合作委员会为诊断ALS提供了一种更简单,更敏感的方法,使得早期和更明确的诊断成为可能.
- 在全球范围内,GCC在临床试验中的更广泛实施正在进行中.
- 未来对遗传生物标志物的验证可能会进一步完善ALS诊断标准和实用性.
相关概念视频
Myasthenia Gravis: Diagnostic Tests
732
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
732
Cross-bridge Cycle
117.2K
As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
117.2K
Parkinson's Disease: Overview
512
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
512
Alzheimer's Disease: Overview
456
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
456


